Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis

American Journal of Clinical Dermatology

Volumn 7, Issue 4, 2006, Pages 213-222

  Abramovits, William ^a,c   Hung, Peter ^b   Tong, Kuo B ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Quorum Consulting Inc   (United States)

^c Texas Dermatology Associates PA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE BUTYRATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; TACROLIMUS;

ACNE; ADRENAL SUPPRESSION; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CAREGIVER; CATARACT; CLINICAL TRIAL; CREAM; DRUG ABSORPTION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG SAFETY; DRY SKIN; GINGIVA HYPERPLASIA; GLAUCOMA; GROWTH RETARDATION; HEALTH STATUS; HUMAN; HYPERTENSION; HYPOPIGMENTATION; LYMPHADENITIS; LYMPHADENOPATHY; LYMPHOMA; MELANOMA; NEPHROTOXICITY; NONHUMAN; OINTMENT; PATIENT INFORMATION; PERIORAL DERMATITIS; PHOTOTHERAPY; POSTMARKETING SURVEILLANCE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; ROSACEA; SARCOMA; SIDE EFFECT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; STRIA; TELANGIECTASIA; TREMOR;

ADMINISTRATION, TOPICAL; CALCINEURIN; DERMATITIS, ATOPIC; ENZYME INHIBITORS; HUMANS;

EID: 33747166430     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607040-00002     Document Type: Review

References (96)

1. Abramovits W. Atopic dermatitis. J Am Acad Dermatol 2005 Jul; 53 (1 Suppl. 1): S86-93
2. Schultz Larsen F, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2003; 22 (1): 1-24
3. Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103 (1 Pt 1): 125-38
4. Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000; 43 (4): 649-55
5. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol 1996; 34 (5 Pt 1): 760-4
6. Sugiura H, Umemoto N, Deguchi H, et al. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm Venereol 1998; 78 (4): 293-4
7. Muto T, Hsieh SD, Sakurai Y, et al. Prevalence of atopic dermatitis in Japanese adults. Br J Dermatol 2003; 148 (1): 117-21
8. Boguniewicz M, Leung DY. Pathophysiologic mechanisms in atopic dermatitis. Semin Cutan Med Surg 2001; 20 (4): 217-25
9. Kang K, Stevens SR. Pathophysiology of atopic dermatitis. Clin Dermatol 2003; 21 (2): 116-21
10. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105 (5): 860-76
11. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361 (9352): 151-60
12. Boguniewicz M, Leung DY. Atopic dermatitis. In: Middleton E, Ellis EF, Yunginger JW, et al., editors. Allergy: principles and practice. 5th ed. St. Louis (MO): Mosby, 1998: 1123-1131
13. Correale CE, Walker C, Murphy L, et al. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 1999; 60 (4): 1191-8
14. Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2003; 44 Suppl. 1: S13-6
15. Boguniewicz M, Nicol N. Conventional therapy for atopic dermatitis. Immunol Allergy Clin North Am 2003; 22 (1): 107-24
16. Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003 May; 148 Suppl. 63: S3-10
17. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4 (37): 1-191
18. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000 May; 142 (5): 931-6
19. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S1-12
20. Leung DYM, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Ann Allergy Clin Immunol 2004; 93: S1-21
21. GlaxoSmithKline. Imuran product information. Uxbridge (UK): GlaxoSmithKline, 2003
22. Roche Laboratories, Inc. CellCept product information. Nutley (NJ): Roche Laboratories Inc., 2005
23. Krutmann J, Diepgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38 (4): 589-93
24. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broadband ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357 (9273): 2012-6
25. Baron ED, Stevens SR. Light treatment modalities for atopic dermatitis. Immunol Allergy Clin North Am 2002; 22 (1): 125-40
26. Harper JI, Berth-Jones J, Camp RD, et al. Cyclosporin for atopic dermatitis in children. Dermatology 2001; 203 (1): 3-6
27. De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991; 71 (5): 452-4
28. Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health 1999; 35: 229-31
29. Eichenfield LF, Hanifin JM, Beck LA, et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003; 111 (3): 608-16
30. Boulay ME, Boulet LP. The relationships between atopy, rhinitis and asthma: pathophysiological considerations. Curr Opin Allergy Clin Immunol 2003; 3 (1): 51-5
31. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? who pays? J Am Acad Dermatol 1993; 28 (5 Pt 1): 699-703
32. Ellis C, Drake L, Prendergast M, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002 Mar; 46: 361-70
33. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol 2001; 144 (3): 514-22
34. Herd RM, Tidman MJ, Prescott RJ, et al. The cost of atopic eczema. Br J Dermatol 1996; 135: 20-3
35. Gieler U, Hohmann M, Niemeier V, et al. Cost evaluation in atopic eczema. J Dermatol Treat 1999; 10: S15-20
36. Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76 (2): 159-62
37. Fivenson D, Arnold RJ, Kaniecki DJ, et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. JMCP 2002; 8 (5): 333-41
38. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001 Jul; 45 (1 Suppl.): S64-6
39. Daud LR, Garralda ME, David TJ. Psychosocial adjustment in preschool children with atopic eczema. Arch Dis Child 1993 Dec; 69 (6): 670-6
40. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health R I 2001 Sep; 84 (9): 294-5
41. Lapidus CS. Role of social factors in atopic dermatitis: the US perspective. J Am Acad Dermatol 2001 Jul; 45 (1 Suppl.): S41-3
42. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S, et al. Sleep disturbance in children with atopic dermatitis. Arch Pediatr Adolesc Med 1994 Aug; 149 (8): 856-60
43. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S65-72
44. Linnet J, Jemec GB. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol 1999 Feb; 140 (2): 268-72
45. Reid P, Lewis-Jones MS. Sleep difficulties and their management in preschoolers with atopic eczema. Clin Exp Dermatol 1995 Jan; 20 (1): 38-41
46. Schiffner R, Schiffner-Rohe J, Landthaler M, et al. Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. PharmacoEconomics 2003; 21 (3): 159-79
47. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 May; 19 (3): 210-6
48. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995 Jun; 132 (6): 942-9
49. Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? J Invest Dermatol 2003; 120 (6): 932-41
50. Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141: 1067-79
51. Friedman JY, Reed SD, Weinfurt KP, et al. Parents' perceptions of the quality of life impact of childhood atopic dermatitis disease states [abstract]. American Academy of Dermatology 61st Annual Meeting; 2003 Mar 21-26; San Francisco (CA) 2003, 19
52. Bekersky I, Fitzsimmons W, Tanase A, et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S17-27
53. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002 Feb; 46 (2): 228-41
54. Reitamo S, Remitz A, Kyllonen H, et al. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol 2002; 3 (6): 381-8
55. Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002; 27 (7): 555-61
56. Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10 (1): 11-8
57. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998 Oct; 102 (4 Pt 1): 637-44
58. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44 (1 Suppl.): S28-38
59. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S47-57
60. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337 (12): 816-21
61. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. European/Canadian Tacrolimus Ointment Study Group. J Allergy Clin Immunol. 2002 Mar; 109 (3): 539-46.
62. Summary for patients in: Curr Allergy Asthma Rep 2002 Jul; 2 (4): 273-4
63. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002 Mar; 109 (3): 557-5
64. Schnopp C, Remling R, Möhrenschlager M, et al. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002 Jan; 46 (1): 73-7
65. Reitamo S, Harper J, Bos JD, et al. 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. European Tacrolimus Ointment Group. Br J Dermatol 2004 Mar; 150 (3): 554-62
66. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136 (8): 999-1006
67. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S58-64
68. Koo JY, Fleischer A, Pariser D, McCall CO. Tacrolimus ointment 0.1% is safe and effective in the treatment for atopic dermatitis: final results of a large (over 7,000 patients) open-label study [abstract]. American Academy of Dermatology 61st Annual Meeting; 2003 Mar 21-26; San Francisco (CA) 2003, P22
69. Paller A, Hanifin J, Eichenfield LF, Clark R. Tacrolimus ointment monotherapy is a safe and effective treatment for atopic dermatitis long-term (more than 3 years) [abstract]. American Academy of Dermatology 61st Annual Meeting; 2003 Mar 21-26; San Francisco (CA) 2003, P24
70. Soter NA, Fleischer Jr AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II. Safety. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S39-46
71. Astellas Pharma, Inc. Protopic package insert. Deerfield (IL): Astellas Pharma, Inc., 2000
72. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998 Jan; 38 (1): 69-76
73. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002 Apr; 46 (4): 495-504
74. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003 Feb; 142 (2): 155-62
75. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002 Aug; 110 (2): 277-84
76. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 Jul; 110 (1 Pt 1): e2
77. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 788-94
78. Novartis Pharmaceuticals. Elidel package insert. East Hanover (NJ): Novartis Pharmaceuticals, 2003
79. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 781-7
80. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001 Mar; 144 (3): 507-13
81. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004 Oct; 51 (4): 515-25
82. Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005 May; 52 (5): 810-22
83. Center for Drug Evaluation and Research, US Food and Drug Administration. Tacrolimus (marketed as Protopic ointment) information [online]. Available from URL: http://www.fda.gov/cder/drμg/infopage/protopic/default.htm [Accessed 2006 May 1]
84. Center for Drug Evaluation and Research, US Food and Drug Administration. Pimecrolimus (marketed as Elidel cream) information [online]. Available from URL: http://www.fda.gov/cder/drμg/infopage/elidel/default.htm [Accessed 2006 May 1]
85. Fonacier L, Spergel J, Charlesworth EN. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005; 115: 1249-53
86. Whalley D, Huels J, McKenna SP, et al. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002; 110 (6): 1133-6
87. Whalley D, McKenna SP, Dewar AL, et al. International development of a measure to assess quality of life in childhood atopic dermatitis: the PIQoL-AD [abstract]. Qual Life Res 2000; 9 (3): 302
88. Whalley D, Huels J, Clegg J, et al. Pimecrolimus (SDZ ASM 981) in the treatment of atopic eczema: benefit to quality of life among infants [abstract]. 20th World Congress of Dermatology; 2003 Jun, Paris, PO283
89. Whalley D, McKenna SP, Huels J, et al. Pimecrolimus (SDZ ASM 981) in the treatment of paediatric atopic eczema: benefit to quality of life and health related quality of life [abstract]. 20th World Congress of Dermatology; 2003 Jun; Paris, PO284
90. Ellis C, Drake L, Prendergast M, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol 2003 Apr; 48 (4): 553-63
91. Ellis CN, Kahler K, Grueger J. Long-term management of atopic dermatitis with pimecrolimus cream 1%: an economic analysis [abstract]. American Academy of Dermatology 61st Annual Meeting; 2003 Mar 21-26; San Francisco (CA) 2003, P205
92. Verboom P, Hakkaart-Van Roijen L, Rutten F, Van Assche D, Grueger J. The cost effectiveness of pimecrolimus (SDZ ASM 981) topical cream 1% and cortico steroids in the treatment of atopic dermatitis [abstract]. American Academy of Dermatology 61st Annual Meeting; 2003 Mar 21-26; San Francisco (CA) 2003, P205
93. Abramovits W, Boguniewicz M, Prendergast MM, et al. Comparisons of efficacy and cost effectiveness of topical immunomodulators in the management of atopic dermatitis. J Med Econ 2003; 6: 1-14
94. Delea T, Gokhale M, Makin C, et al. Medical-care utilization in health-plan members with atopic dermatitis receiving topical corticosteroids who initiate therapy with pimecrolimus or tacrolimus [abstract]. AMCP Educational Conference; 2005 Oct, Nashville (TN)
95. Williams H. New treatments for atopic dermatitis. BMJ 2002; 324 (7353): 1533-4
96. Abramovits W, Goldstein A, Stevenson L. Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis. Clinics in Dermatology 2003; 21: 383-91